Shengtai Pharmaceutical, Inc. Appoin...(through its wholly-owned subsidiarySheng...)
Navigation Links
| HOME >> BIOLOGY >> TECHNOLOGY |
Shengtai Pharmaceutical, Inc. Appoints New CFO
Date:5/1/2008
through its wholly-owned subsidiary Shengtai Holding, Inc. (SHI), a New Jersey corporation, and the Chinese operating company Weifang Shengtai Pharmaceutical Co., Ltd., is a leading manufacturer and supplier of glucose products, which include pharmaceutical grade glucose used for medical purposes, and glucose and cornstarch products for the food and beverage industry and for industrial production in China. For more information about Shengtai Pharmaceutical, Inc. please visit http://www.shengtaipharmaceutical.com .
Safe Harbor Statement
Safe Harbor Statement Under the Private Securities Litigation Reform
Act of 1995: Certain statements in this press release and oral statements
made by the Company, constitute forward-looking statements for purposes of
the safe harbor provisions under The Private Securities Litigation Reform
Act of 1995. These statements include, without limitation, statements
regarding our ability to prepare the company for growth and our ability to
improve communication with investors and improve disclosure. We have based
these forward-looking statements largely on our current expectations and
projections about future events and financial trends that we believe may
affect our financial condition, results of operations, business strategy
and financial needs but they involve risks and uncertainties that could
cause actual results to differ materially from those in the forward-looking
statements, which may include, but are not limited to, such factors as
unanticipated changes in product demand in the pharmaceutical industry,
pricing and demand trends for the Company's products, changes to government
regulations, risk associated with operation of the Company's new
facilities, risk associated with large scale implementation of the
Company's business plan, the ability to attract new customers, the ability
to increase its products' applications, the cost of raw materials,
downtu
'/>"/>
| SOURCE Shengtai Pharmaceutical, Inc. Copyright©2008 PR Newswire. All rights reserved |
Related biology technology :
1. Shengtai Pharmaceutical, Inc. Announces Conference Call to Discuss Second Quarter Results of Fiscal Year 2008
2. DOV Pharmaceutical, Inc. Begins Trading on OTC Bulletin Board
3. Mindray to Present at Merrill Lynch Global Pharmaceutical, Biotech & Medtech Conference
4. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotech & Medtech 2007 Conference
5. Merrill Lynch Global Pharmaceutical, Biotech and Medtech Conference to Webcast Millennium Presentation
6. Schering-Plough to Webcast Presentation at Merrill Lynch Global Pharmaceutical, Biotech & Medtech Conference
7. Strativa Pharmaceuticals, the Proprietary Products Division of Par Pharmaceutical, Provides an Update on Development Status of Pafuramidine and Other in-Licensed Products
8. A New, Unique and Unrivalled Rat/Mouse PINP Assay for Pharmaceutical, Clinical and Academic Research Organizations.
9. Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference to Webcast Alexzas Corporate Presentation
10. Allos Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference
11. Thermo Fisher Scientific to Present at the 2008 Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
Post Your Comments:
Breaking Biology Technology:AEterna Zentaris Announces Results from its European Phase 3 Study with Cetrorelix in Benign Prostatic Hyperplasia 2AEterna Zentaris Announces Results from its European Phase 3 Study with Cetrorelix in Benign Prostatic Hyperplasia 334th Annual Hutch Holiday Gala Raises More Than $7 Million For Cancer Research 234th Annual Hutch Holiday Gala Raises More Than $7 Million For Cancer Research 3Stemline Therapeutics Announces Poster Presenting in vivo and Anti-Cancer Stem Cell Activity of SL-401 against Chronic Myeloid Leukemia (CML) at the 51st Annual Meeting of the American Society of Hematology (ASH) 2VIA Pharmaceuticals Completes Patient Visits in Phase 2 Trial of VIA-2291 2VIA Pharmaceuticals Completes Patient Visits in Phase 2 Trial of VIA-2291 3VIA Pharmaceuticals Completes Patient Visits in Phase 2 Trial of VIA-2291 4
[0] AEterna Zentaris Announces Results from its European Phase 3 Study with Cetrorelix in Benign Prostatic Hyperplasia[0] 34th Annual Hutch Holiday Gala Raises More Than $7 Million For Cancer Research[0] Stemline Therapeutics Announces Poster Presenting in vivo and Anti-Cancer Stem Cell Activity of SL-401 against Chronic Myeloid Leukemia (CML) at the 51st Annual Meeting of the American Society of Hematology (ASH)[0] VIA Pharmaceuticals Completes Patient Visits in Phase 2 Trial of VIA-2291
Other Biology Technology:New Study Reports That Ablative Therapy With HALO360 Device Effectively Treats Highest-Risk Category of Barrett's Esophagus 2New Study Reports That Ablative Therapy With HALO360 Device Effectively Treats Highest-Risk Category of Barrett's Esophagus 3China Biologic Products Reports First Quarter 2008 Results 2China Biologic Products Reports First Quarter 2008 Results 3China Biologic Products Reports First Quarter 2008 Results 4China Biologic Products Reports First Quarter 2008 Results 5China Biologic Products Reports First Quarter 2008 Results 6China Biologic Products Reports First Quarter 2008 Results 7China Biologic Products Reports First Quarter 2008 Results 8China Biologic Products Reports First Quarter 2008 Results 9China Biologic Products Reports First Quarter 2008 Results 10ImaRx Therapeutics Reports First Quarter Ended 2008 Financial Results 2ImaRx Therapeutics Reports First Quarter Ended 2008 Financial Results 3ImaRx Therapeutics Reports First Quarter Ended 2008 Financial Results 4ImaRx Therapeutics Reports First Quarter Ended 2008 Financial Results 5ImaRx Therapeutics Reports First Quarter Ended 2008 Financial Results 6ImaRx Therapeutics Reports First Quarter Ended 2008 Financial Results 7
Breaking Biology News(10 mins):Study shows nearly 1/3 of human genome is involved in gingivitis 2Study shows nearly 1/3 of human genome is involved in gingivitis 3Einstein receives high-risk/high-reward cancer research funding 2Einstein receives high-risk/high-reward cancer research funding 3Stem cells battle for space 2BioSpecifics Technologies Corp to Present at CapStone Investments Third Annual Small Cap Investor Conference 13157 1Medifast Independent Director Lt Gen Dennis McCarthy Confirmed as Assistant Secretary of Defense for Reserve Affairs 52466 1Medifast Independent Director Lt Gen Dennis McCarthy Confirmed as Assistant Secretary of Defense for Reserve Affairs 52466 2Medifast Independent Director Lt Gen Dennis McCarthy Confirmed as Assistant Secretary of Defense for Reserve Affairs 52466 3Orexigen 28R 29 Therapeutics Announces Proposed Public Offering of Common Stock 52464 1Orexigen 28R 29 Therapeutics Announces Proposed Public Offering of Common Stock 52464 2
| Copyright © 2003-2009 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |